• About PEGASYS + COPEGUS Combination Therapy
• The Benefits of Treatment
• PEGASYS Dosing
• Efficacy Across the Broadest Range of Patients
• Efficacy for Patients With HCV/HIV Coinfection
• Efficacy for Patients With Hepatitis B
• Safety and Tolerability
• Patient Support
• Resource Library
• Healthcare Professional Tools
• Guide to PEGASYS Prefilled Syringes

PEGASYS is the first and only FDA-approved treatment for HCV/HIV coinfected patients.

PEGASYS + COPEGUS^® (Ribavirin, USP) performed with superior efficacy over interferon alfa-2a + ribavirin in the APRICOT* study—the largest-ever trial in HCV/HIV coinfected patients.¹

Overall, 40% of patients treated with PEGASYS + COPEGUS achieved a sustained virologic response (SVR).¹

The SVR rate for patients with genotype 1 who were treated with PEGASYS + COPEGUS was 29%—more than 4 times higher than with interferon + ribavirin.¹ Among patients taking 80% or more of their planned medication over the course of treatment, the response rate increased to 39%.²

The SVR response rate for patients treated with PEGASYS + COPEGUS was 62% for HCV genotypes 2 and 3—more than 3 times higher than the response rate with interferon alfa-2a + ribavirin.¹

• An overall SVR of 30% was observed in patients (13/44) with bridging fibrosis/cirrhosis who were treated with PEGASYS + COPEGUS.³
• The overall efficacy and safety of PEGASYS + COPEGUS was not adversely affected by baseline CD4 count in APRICOT, although the number of patients with CD4 <200 was small^.†2

*APRICOT consisted of 860 HCV/HIV coinfected patients who randomly received either PEGASYS + COPEGUS, PEGASYS + placebo, or interferon alfa-2a + ribavirin for 48 weeks. Of these patients, 809 had ≥200 cells/mm regardless of HIV RNA levels and 51 had 100-199 cells/mm in HIV RNA <5000 copies/mL.

^†Patient numbers (n=17) were very small and no firm conclusions can be drawn from this.

Treating patients with PEGASYS may result in a histologic response.⁴

In patients with paired biopsies:

• 87% of the patients overall and 95% of patients with bridging fibrosis/cirrhosis treated with PEGASYS + COPEGUS showed either a histologic response or remained stable.^4,5

^‡Histologic response was defined as ≥2-point reduction from baseline in the total histologic activity index (HAI) score. No change was defined as a change in HAI score of +1, -1, or 0; worsening was defined as an increase in HAI score of ≥2 points.

All paired biopsies were scored by local pathologists.

In patients without an SVR:

• 77% of overall HCV/HIV patients (47/61) achieved a histologic response or remained stable.⁵
• 58% of HCV/HIV patients (7/12) with bridging fibrosis/cirrhosis achieved a histologic response.⁴

1. Torriani FJ et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
2. Opravil M et al. Treatment exposure and sustained virologic response (SVR) in genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEG IFN a2a) + ribavirin (RBV) in APRICOT (AIDS PEGASYS Ribavirin International Co-infection Trial). Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 21-24, 2005; New Orleans, La.
3. Sasadeusz J et al. Safety and efficacy of Peginterferon alfa-2a (40KD) (PEGASYS^®) plus ribavirin (COPEGUS^®) in HIV-HCV co-infected patients with cirrhosis/bridging fibrosis: results of the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2004; Boston, Mass.
4. Lissen E. Histological response to peginterferon alfa-2a (40KD) (PEGASYS^®) plus ribavirin (COPEGUS^®) in HIV-HCV co-infection; the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
5. Nelson M. Histological response to peginterferon alfa-2a (40KD) (PEGASYS^®) plus ribavirin (COPEGUS^®) in patients with HIV-HCV co-infection: results of the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2004; Boston, Mass.